Newsflash Asia – Breaking Stories, Smarter and Faster

Today Free Charge

Join the Community

ClavystBio and A*STAR boost Singapore’s MedTech ventures

Newsflash Asia

- June 10, 2025

ClavystBio, a life sciences investor established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector R&D agency, have signed a Memorandum of Understanding (MoU) to foster MedTech ventures in Singapore. This collaboration will leverage ClavystBio’s venture-building expertise and A*STAR’s scientific capabilities to support venture creation, product development, and commercialisation.

The partnership is timely, as Singapore’s MedTech output reached S$20b in 2023, with Asia’s MedTech market projected to grow to $225b (S$304b) by 2030. Over the next two years, the collaboration will focus on co-creating new ventures, investing in A*STAR-affiliated companies, and fostering collaborations between A*STAR and ClavystBio’s portfolio companies.

Key areas of focus include:

– **Fostering new ventures:** A*STAR and ClavystBio will identify promising research to build new MedTech companies, combining scientific expertise with venture capital and guidance.

– **Advancing product development:** MedTech Catapult will aid in developing medical devices, whilst ClavystBio will explore commercial pathways for innovations.

– **Accelerating commercial readiness:** DxD Hub and ClavystBio will shape ventures in diagnostics and digital health, focusing on commercial viability.

– **Strengthening the ecosystem:** The partnership will assess Singapore’s MedTech landscape to identify gaps and investment opportunities.

Anselm Tan, Digital Health and MedTech Lead at ClavystBio, stated, “By combining ClavystBio’s investment and venture-building expertise with A*STAR’s deep scientific capabilities, we are cultivating an ecosystem primed for innovation and commercial success.” Irene Cheong, Assistant Chief Executive of Innovation and Enterprise at A*STAR, added, “This MoU marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures.”

This partnership aims to position Singapore as a leader in MedTech innovation, potentially transforming the local and regional landscape.
“`

This story was selected and published by a human editor, with content adapted from original press material using AI tools. Spot an error? Report it here.

x Studio

Connect with your clients by working with our in-house brand studio, using our expertise and media reach to help you create and craft your message in video and podcast, native content and whitepapers, webinars and event formats
[the_ad id="889990"]
[the_ad id="889991"]
[the_ad id="889992"]
[the_ad id="889977"]
[the_ad id="889994"]
[the_ad id="889993"]

Warning: Attempt to read property "post_status" on null in /var/www/html/wp-admin/includes/template.php on line 2298

Warning: Attempt to read property "post_status" on null in /var/www/html/wp-admin/includes/template.php on line 2302

Warning: Attempt to read property "post_status" on null in /var/www/html/wp-admin/includes/template.php on line 2308

Warning: Attempt to read property "post_status" on null in /var/www/html/wp-admin/includes/template.php on line 2312

Warning: Attempt to read property "ID" on null in /var/www/html/wp-admin/includes/template.php on line 2316

Warning: Attempt to read property "post_status" on null in /var/www/html/wp-admin/includes/template.php on line 2320

Warning: Attempt to read property "ID" on null in /var/www/html/wp-admin/includes/template.php on line 2325

Warning: Attempt to read property "ID" on null in /var/www/html/wp-admin/includes/template.php on line 2329

Warning: Attempt to read property "ID" on null in /var/www/html/wp-admin/includes/template.php on line 2334